34 Participants Needed

Azacitidine + Nivolumab for Brain Cancer

AG
Overseen ByAndrew Groves, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, you must be on a stable or decreasing dose of corticosteroids for at least 7 days before enrollment.

What data supports the effectiveness of the drug combination Azacitidine and Nivolumab for brain cancer?

Research shows that Nivolumab, part of the drug combination, has shown some effectiveness in treating brain metastases (cancer spread to the brain) in patients with non-small cell lung cancer, with some patients experiencing a reduction in brain tumors. This suggests potential for Nivolumab's effectiveness in brain cancer treatment.12345

Is the combination of Azacitidine and Nivolumab safe for humans?

Nivolumab, used in combination with other drugs, has shown some safety concerns, including immune-related side effects like fatigue, nausea, and more serious neurological effects such as encephalitis (brain inflammation). However, these effects are often reversible with appropriate treatment, and the drug has been used safely in various cancer treatments.13678

How is the drug combination of Azacitidine and Nivolumab unique for brain cancer treatment?

The combination of Azacitidine and Nivolumab for brain cancer is unique because Nivolumab is an immune checkpoint inhibitor that helps the immune system attack cancer cells, and it has shown potential intracranial activity in other cancers like melanoma and lung cancer. This approach is novel as it leverages the immune system to target brain cancer, which is challenging due to the blood-brain barrier that typically limits drug delivery.1591011

What is the purpose of this trial?

This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.

Eligibility Criteria

This trial is for patients with recurrent high-grade glioma, a type of brain cancer. Participants must have specific forms of this condition, such as Glioblastoma or Diffuse Midline Glioma. Detailed inclusion and exclusion criteria are not provided but would typically involve health status and prior treatments.

Inclusion Criteria

At least one measurable lesion per RANO 2.0 meeting specific criteria
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours of starting therapy
WOCBP must agree to follow instructions for methods of contraception
See 14 more

Exclusion Criteria

Subjects with major medical, neurologic, or psychiatric condition who are judged to be unable to fully comply with trial therapy or assessments
Patients with a history of pneumonitis
History of allergy to trial drug components
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intrathecal azacitidine and nivolumab with dose escalation and monitoring for safety and efficacy

24 months
Visits on days 1, 8, and 22 of cycle 1; days 1 and 15 of subsequent cycles; MRI every 8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Azacitidine
  • Intrathecal Administration
  • Nivolumab
Trial Overview The study tests the safety and effectiveness of azacitidine (AZA) and nivolumab delivered directly into the spinal fluid via lumbar puncture in treating recurrent high-grade gliomas. It's an early-phase trial where everyone gets both drugs to see how well they work together.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (IT nivolumab + IT azacitidine)Experimental Treatment4 Interventions
Patients will receive intrathecal azacitidine on day 1, 8, and 22 of cycle 1 (34 day cycle). Intrathecal nivolumab will be given at a flat dose of 40 mg on day 8 and 22. Each subsequent cycle will be 28 days with intrathecal azacitidine and intrathecal nivolumab given on days 1 and 15. Intrathecal azacitidine will be dose-escalated with 4 dose levels (5, 10, 20, 40 mg) using a 3+3 design. Patients may continue on study in the absence of disease progression or unacceptable toxicity. Patients will have CSF and blood specimen collection on days 1 and 8 of cycle 1, and then day 1 of every-other cycle starting with cycle 2. Patients will undergo MRI at baseline, then every 8 weeks (e.g. after cycle 3, cycle 5, etc...).

Find a Clinic Near You

Who Is Running the Clinical Trial?

Andrew P. Groves

Lead Sponsor

Trials
1
Recruited
30+

Findings from Research

In a retrospective study of five patients with advanced non-small cell lung cancer (NSCLC) and new or progressing brain metastases, nivolumab showed promising intracranial activity, with one complete and one partial response observed, and stabilization of leptomeningeal carcinomatosis in another patient.
Nivolumab was well-tolerated, with no severe treatment-related adverse events reported, suggesting a favorable safety profile for patients with CNS metastases from NSCLC.
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.Dudnik, E., Yust-Katz, S., Nechushtan, H., et al.[2022]
In a study of 66 patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab, those with a poor performance status (PS ≥2) had a significantly shorter median overall survival of 3.04 months compared to 10.23 months for those with better performance status (PS ≤1).
Despite similar rates of treatment-related adverse events between the two groups, the findings suggest that performance status is a crucial factor in predicting survival outcomes and should be considered when selecting immunotherapy treatments for lung cancer.
Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer.Abbas, MN., Klevansky, M., Koczwara, B., et al.[2022]
In a Phase II study involving 18 patients with leptomeningeal disease, the combination of ipilimumab and nivolumab showed promising efficacy, with 44% of patients alive at three months, surpassing the expected 18%.
The treatment had an acceptable safety profile, although one-third of patients experienced significant adverse events, including two cases leading to treatment discontinuation due to hepatitis and colitis.
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.Brastianos, PK., Strickland, MR., Lee, EQ., et al.[2021]

References

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. [2022]
Real-world experience of nivolumab in the treatment of poor performance status patients with advanced non-small cell lung cancer. [2022]
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. [2021]
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. [2022]
Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. [2021]
Nivolumab-Associated Acute Demyelinating Encephalitis: A Case Report and Literature Review. [2020]
Complications associated with immunotherapy for brain metastases. [2023]
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. [2018]
Bilateral Optic Neuritis Secondary to Nivolumab Therapy: A Case Report. [2019]
10.United Statespubmed.ncbi.nlm.nih.gov
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. [2022]
Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security